Department of Pharmacy, University of Washington, Seattle, Washington, USA.
Department of Psychology, University of California - Los Angeles, Los Angeles, California, USA.
Clin Pharmacol Ther. 2021 Oct;110(4):897-908. doi: 10.1002/cpt.2234. Epub 2021 May 2.
The transgender adult population is growing globally, but clinical pharmacology has lagged behind other areas of transgender medicine. Medical care for transgender adults may include long-term testosterone or estrogen treatment to align secondary sex characteristics with gender identity. Clinicians often use drug-drug interaction data from the general adult population to predict medication disposition or safety among transgender adults. However, this approach does not address the complex pharmacodynamic effects of hormone therapy in transgender adults. In this review, we critically examine sex-related and gender-related differences in clinical pharmacology and apply these data to discuss current gaps in transgender medicine.
全球跨性别成年人的数量不断增加,但临床药理学的发展却落后于跨性别医学的其他领域。跨性别成年人的医疗护理可能包括长期的睾酮或雌激素治疗,以使其第二性征与性别认同相符。临床医生通常使用来自一般成年人群的数据来预测药物在跨性别成年人中的处置或安全性。然而,这种方法并不能解决激素治疗对跨性别成年人的复杂药效学影响。在这篇综述中,我们批判性地检查了临床药理学中的性别和性别相关差异,并应用这些数据来讨论跨性别医学中的当前差距。